ARTHUR-D.-LITTLE
15.3.2022 10:02:08 CET | Business Wire | Press release
Arthur D. Little (ADL) today announced the promotion of nine of its consultants to the rank of Partner across a number of its global offices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220315005634/en/
Each new Partner has demonstrated their commitment to ADL, passion and dedication to the industries and clients they serve, and best-in-class experience and expertise. ADL credits a lot of its ongoing growth and success to the development, promotion and retention of its internal talent, with a recent survey on Vault acknowledging these values for setting ADL apart as an employer.
The latest promotions to Partner are as follows:
- Ryan Alnesayan, Partner, Public Services Practice, Riyadh. Leading ADL Riyadh’s office, Ryan has over 14 years of consulting and business advisory experience in strategic planning, economic development, and large-scale transformation projects, with a focus on Saudi Arabia.
- Marcus Beard, Partner, Risk Practice, Cambridge. Marcus’ area of expertise is risk management, in which he primarily focuses on developing next-generation risk management approaches, culture assessment, safety and risk governance and assurance, risk analysis, and executive leadership training, with deep industry experience in travel & transportation.
- Dr. Engin Beken, Partner, Operations Management Practice, Frankfurt & Vienna. Engin is a key expert in strategic performance improvement and digitalization. He is a strong contributor to ADL’s global operations management practice and works with our clients globally, especially in asset-heavy industries.
- Florence Carlot, Partner, Energy & Utilities Practice, Brussels. Florence focuses on strategy and organization in the energy & utilities industry. She has been working within the European energy and utilities sector for over 15 years, enabling large operational and strategic change initiatives across the energy value chain.
- Julien Duvaud-Schelnast, Partner, Telecommunications, Information Technology, Media & Electronics (TIME) Practice, Paris & Stockholm. Operating in both France and Sweden, Julien is an expert on trending topics within the TIME practice, including infrastructure, private networks and sustainability.
- Dr. Michael Eiden, Partner, Technology & Innovation Practice, London. Michael is the Global Head of Artificial Intelligence and Machine Learning at ADL. He is an industry expert with more than 20 years of hands-on experience in designing, developing and commercializing AI solutions in different industries.
- Ben Enejo, Partner, Healthcare & Life Sciences Practice, Boston. Ben is an experienced management consultant and industry expert, having worked with various global biopharmaceutical companies on strategies to accelerate the development of new medicines through to commercialization. Particular areas of expertise include clinical trial acceleration; R&D transformation, including advanced technology application, increasing success for rare-disease drug development and launch; patient and drug safety; and quality and compliance excellence.
- Mitsuhiro Henry Umebayashi, Partner, Strategy & Organization Practice, Singapore. Henry leads the S&O practice in South-East Asia and supports clients from multiple industries, such as consumer goods, energy & utilities, infrastructure and healthcare. His main focus is supporting clients with business transformation and growth acceleration arising from management challenges such as sustainability, globalization and digitalization.
- Arjun Vir Singh, Partner, Financial Services Practice, Dubai. Arjun joined ADL in 2020 as the Head of Financial Services for the Middle East region. Actively engaged with fintech, payments, and digital banking, as well as the wider start-up ecosystem across the Middle East region and beyond, Arjun has deep sectorial knowledge. He has launched and managed a payments and fintech business for a large conglomerate across multiple markets in the Middle East and SEA region.
Ignacio Garcia Alves, Chairman and Chief Executive Officer of Arthur D. Little , comments: “I would like to congratulate our nine new Partners, who have worked hard and smart to become true entrepreneurs. Each promotion is richly deserved, and we are extremely grateful for the role they have played in the firm. At ADL we place tremendous value on our people. These nine colleagues have shown they are ready for the next step of their careers, and we are truly excited as they enter into their era of partnership.”
About Arthur D. Little
Arthur D. Little has been at the forefront of innovation since 1886. We are an acknowledged thought leader in linking strategy, innovation and transformation in technology-intensive and converging industries. We navigate our clients through changing business ecosystems to uncover new growth opportunities. We enable our clients to build innovation capabilities and transform their organizations.
Our consultants have strong practical industry experience combined with excellent knowledge of key trends and dynamics. ADL is present in the most important business centers around the world. We are proud to serve most of the Fortune 1000 companies, in addition to other leading firms and public sector organizations.
For further information, please visit www.adlittle.com or www.adl.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005634/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
